Comment on “Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors”

Lignende værker

• Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors
  af: Kim, Sung-Hyun, et al.
  Udgivet: (2014)
• Radotinib in the treatment of chronic phase chronic myeloid leukemia patients
  af: Eskazan, Ahmet Emre, et al.
  Udgivet: (2015)
• c-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia
  af: Lucas, Claire M., et al.
  Udgivet: (2015)
• Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia
  af: de Almeida, Maria Helena, et al.
  Udgivet: (2014)
• Mutant BCR-ABL clones in chronic myeloid leukemia
  af: Mathisen, Michael S., et al.
  Udgivet: (2011)